Gamma Brief Lab

← Tous les modules

La dose invisible

Un traitement par ¹⁷⁷Lu-DOTATATE, dans la peau du médecin nucléaire : prescrire, voir, mesurer, represcrire

médianes et plages des études : Données publiéesdoses estimées et tendances : Ordre de grandeurpatients virtuels : Illustratifmontée des premières heures : Illustratif En relecture

Ouvrir l'expérience en plein écran ↗

Sources

  1. Kayal G, et al. Multicycle dosimetric behavior and dose-effect relationships in [177Lu]Lu-DOTATATE peptide receptor radionuclide therapy. J Nucl Med. 2025;66(6):900-908. · doi:10.2967/jnumed.124.269389
  2. Macsuka MJ, et al. Cumulative absorbed dose and successive cyclic reduction in absorbed dose predict response to 177Lu-DOTATATE in neuroendocrine tumors. J Nucl Med. 2026;67(5):751-757. · doi:10.2967/jnumed.125.271039
  3. Hebert K, et al. Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE: one step closer to personalized medicine. J Nucl Med. 2024;65(6):923-930. · doi:10.2967/jnumed.123.267023
  4. Bergsma H, et al. Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 2016;43:1802-1811. · doi:10.1007/s00259-016-3382-9
  5. Hänscheid H, et al. Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75-81. · doi:10.2967/jnumed.117.193706
  6. Peters SMB, et al. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging. 2022;49:460-469. · doi:10.1007/s00259-021-05471-4
  7. Sundlöv A, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49:3830-3840. · doi:10.1007/s00259-022-05786-w
  8. Del Prete M, et al. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46:728-742. · doi:10.1007/s00259-018-4209-7
  9. Deshayes E, et al. Patient-specific dosimetry-driven PRRT: time to move forward! J Nucl Med. 2025;66(6):983. · doi:10.2967/jnumed.124.268880
  10. Sundlöv A, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480-1489. · doi:10.1007/s00259-017-3678-4

v1.1.0 · dernière vérification 2026-09-29